Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed. So, the natural question for Biomea Fusion (NASDAQ:BMEA) ...

REDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery ...

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Biomea Fusion (BMEA – Research Report), retaining the price target ...

Biomea Fusion, Inc. (NASDAQ:BMEA – Get Free Report) has been given an average recommendation of “Buy” by the twelve analysts that are covering the firm, Ratings reports. Two research analysts have ...

Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral ...

On Thursday, Biomea Fusion Inc (BMEA) stock saw a decline, ending the day at $9.37 which represents a decrease of $-0.97 or -9.38% from the prior close of $10.34. The stock opened at $10.46 and ...

Pre-earnings options volume in Biomea Fusion (BMEA) is normal with calls leading puts 9:2. Implied volatility suggests the market is anticipating a move near 6.1%, or 75c, after results are released.

On Tuesday, Truist Securities adjusted its stance on Biomea Fusion Inc. (NASDAQ:BMEA) stock, moving from a Buy to a Hold rating. This decision comes in the wake of a clinical hold... On Monday, H ...

REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to ...

U.S. Food and Drug Administration (FDA) lifted Clinical Hold on COVALENT-111 (Type 2 Diabetes) & COVALENT-112 (Type 1 Diabetes) ...